IRMD
Price
$53.60
Change
+$0.15 (+0.28%)
Updated
Apr 2 closing price
Capitalization
557.04M
28 days until earnings call
VREX
Price
$11.43
Change
-$0.00 (-0.00%)
Updated
Apr 2 closing price
Capitalization
732.76M
33 days until earnings call
Ad is loading...

IRMD vs VREX

Header iconIRMD vs VREX Comparison
Open Charts IRMD vs VREXBanner chart's image
iRadimed
Price$53.60
Change+$0.15 (+0.28%)
Volume$22.78K
Capitalization557.04M
Varex Imaging
Price$11.43
Change-$0.00 (-0.00%)
Volume$225.39K
Capitalization732.76M
IRMD vs VREX Comparison Chart
Loading...
IRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VREX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IRMD vs. VREX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRMD is a StrongBuy and VREX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (IRMD: $53.60 vs. VREX: $11.43)
Brand notoriety: IRMD and VREX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: IRMD: 56% vs. VREX: 47%
Market capitalization -- IRMD: $557.04M vs. VREX: $732.76M
IRMD [@Medical Specialties] is valued at $557.04M. VREX’s [@Medical Specialties] market capitalization is $732.76M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IRMD’s FA Score shows that 2 FA rating(s) are green whileVREX’s FA Score has 0 green FA rating(s).

  • IRMD’s FA Score: 2 green, 3 red.
  • VREX’s FA Score: 0 green, 5 red.
According to our system of comparison, IRMD is a better buy in the long-term than VREX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IRMD’s TA Score shows that 4 TA indicator(s) are bullish while VREX’s TA Score has 4 bullish TA indicator(s).

  • IRMD’s TA Score: 4 bullish, 3 bearish.
  • VREX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, IRMD is a better buy in the short-term than VREX.

Price Growth

IRMD (@Medical Specialties) experienced а +1.55% price change this week, while VREX (@Medical Specialties) price change was -7.15% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.40%. For the same industry, the average monthly price growth was +3.95%, and the average quarterly price growth was +3.94%.

Reported Earning Dates

IRMD is expected to report earnings on May 01, 2025.

VREX is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Medical Specialties (-1.40% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VREX($733M) has a higher market cap than IRMD($557M). IRMD has higher P/E ratio than VREX: IRMD (31.84) vs VREX (18.22). IRMD YTD gains are higher at: -2.250 vs. VREX (-21.659). VREX has higher annual earnings (EBITDA): 85.6M vs. IRMD (20.8M). VREX has more cash in the bank: 141M vs. IRMD (49.8M). IRMD has less debt than VREX: IRMD (2.04M) vs VREX (470M). VREX has higher revenues than IRMD: VREX (878M) vs IRMD (65.6M).
IRMDVREXIRMD / VREX
Capitalization557M733M76%
EBITDA20.8M85.6M24%
Gain YTD-2.250-21.65910%
P/E Ratio31.8418.22175%
Revenue65.6M878M7%
Total Cash49.8M141M35%
Total Debt2.04M470M0%
FUNDAMENTALS RATINGS
IRMD vs VREX: Fundamental Ratings
IRMD
VREX
OUTLOOK RATING
1..100
1053
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
83
Overvalued
PROFIT vs RISK RATING
1..100
26100
SMR RATING
1..100
3993
PRICE GROWTH RATING
1..100
5079
P/E GROWTH RATING
1..100
3439
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRMD's Valuation (15) in the Medical Specialties industry is significantly better than the same rating for VREX (83). This means that IRMD’s stock grew significantly faster than VREX’s over the last 12 months.

IRMD's Profit vs Risk Rating (26) in the Medical Specialties industry is significantly better than the same rating for VREX (100). This means that IRMD’s stock grew significantly faster than VREX’s over the last 12 months.

IRMD's SMR Rating (39) in the Medical Specialties industry is somewhat better than the same rating for VREX (93). This means that IRMD’s stock grew somewhat faster than VREX’s over the last 12 months.

IRMD's Price Growth Rating (50) in the Medical Specialties industry is in the same range as VREX (79). This means that IRMD’s stock grew similarly to VREX’s over the last 12 months.

IRMD's P/E Growth Rating (34) in the Medical Specialties industry is in the same range as VREX (39). This means that IRMD’s stock grew similarly to VREX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IRMDVREX
RSI
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 15 days ago
64%
Declines
ODDS (%)
Bearish Trend 13 days ago
58%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
65%
View a ticker or compare two or three
Ad is loading...
IRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VREX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSCGX16.620.24
+1.47%
Thrivent Small Cap Growth S
NBPIX46.44N/A
N/A
Neuberger Berman Large Cap Value Instl
FSCTX21.74N/A
N/A
Fidelity Advisor Small Cap M
GPTUX12.96N/A
N/A
GuidePath® Tactical Allocation Svc
RSMMX8.94N/A
N/A
Victory RS Small Cap Equity Member